What Is Lyrica Prescribed For? Uses and Side Effects

Lyrica is the brand name for pregabalin, a prescription medication with five FDA-approved uses: diabetic nerve pain, pain after shingles, fibromyalgia, neuropathic pain from spinal cord injury, and partial-onset seizures in epilepsy. Outside the United States, it is also approved for generalized anxiety disorder. The drug works differently than most people assume from its name, which sounds vaguely related to mood, and its side-effect profile includes some risks that deserve more attention than they typically get.

How Pregabalin Actually Works

Pregabalin was originally designed to mimic GABA, a calming brain chemical. But researchers discovered it does not actually work through GABA pathways at all. Instead, it binds tightly to a specific part of calcium channels on nerve cells, called the α2δ subunit. By latching onto that subunit, it reduces the flow of calcium into the cell, which in turn dials down the release of several excitatory neurotransmitters.

¹ Think of it as turning down the volume on overactive nerve signaling. That single mechanism explains why one drug can treat conditions as different as seizures, nerve pain, and anxiety: all three involve nerves firing more than they should.

The drug’s pharmacokinetics are unusually clean. It is absorbed quickly, its absorption scales predictably with dose, and almost none of it is broken down by the liver. Less than 2% is metabolized; the rest is cleared unchanged by the kidneys. It does not interact with the cytochrome P450 enzyme system, which means it has very few drug-drug interactions compared to many other neurological medications.² That kidney-dependent clearance matters, though: if your kidney function is reduced, the drug builds up faster, and doses need to be lowered accordingly.

Nerve Pain From Diabetes and Shingles

The two neuropathic pain conditions Lyrica was first approved for are painful diabetic peripheral neuropathy and postherpetic neuralgia, the lingering nerve pain that can follow a shingles outbreak. These are its most established uses, and the evidence behind them is solid.

For diabetic nerve pain, a randomized trial found that pregabalin at 600 mg per day dropped average pain scores meaningfully compared to placebo, and roughly 40% of patients experienced at least a 50% reduction in pain, compared to about 15% on placebo.³ A separate withdrawal trial showed that patients who responded to pregabalin maintained their pain relief significantly longer before losing that response, and sleep quality also improved.⁴

For postherpetic neuralgia, the story is similar. Pregabalin has shown consistent efficacy in relieving pain and improving the sleep disruption that frequently accompanies the condition.⁵ Sleep disruption matters here because chronic nerve pain and poor sleep feed each other in a vicious cycle, so improving both simultaneously is a meaningful clinical win.

Fibromyalgia

In 2007, Lyrica became the first drug approved by the FDA specifically for fibromyalgia, a condition characterized by widespread pain, fatigue, and sleep problems. Five placebo-controlled trials demonstrated that pregabalin reduces pain and improves both sleep and overall quality of life in fibromyalgia patients.⁶

The sleep improvements are especially well documented. Objectively measured, pregabalin-treated patients had fewer wake-sleep transitions during the night and longer uninterrupted sleep bouts, averaging about 15 minutes per bout compared to roughly 12 minutes on placebo.⁷ An analysis across multiple trials found that improvements in both pain and sleep quality appeared as early as the first or second day of treatment, though sustained clinical improvement took longer to establish.⁸

That said, fibromyalgia is notoriously difficult to treat, and pregabalin does not work for everyone. Many patients experience partial relief rather than a dramatic transformation, and the side effects (particularly weight gain and cognitive fog) sometimes limit how long people stay on the medication.

Spinal Cord Injury Pain

Neuropathic pain after spinal cord injury is one of the most challenging pain conditions to manage. Pregabalin is currently the only FDA-approved drug specifically indicated for this type of pain.⁹ A network meta-analysis comparing several medications found that pregabalin ranked highest in reducing average pain intensity, ahead of gabapentin, amitriptyline, and carbamazepine.¹⁰ Being the only approved option does not mean it is the only drug used in practice, but it does mean the evidence base is strongest here.

Epilepsy

Pregabalin is approved as an add-on treatment for partial-onset seizures in adults. It is not used alone for epilepsy and is not approved for generalized seizure disorders. The evidence comes from multiple large trials involving well over a thousand patients, which showed a clear dose-response relationship: higher doses of pregabalin resulted in greater reductions in seizure frequency.¹¹ Long-term open-label studies have also confirmed its safety and effectiveness when used continuously.¹²

In pediatric patients, a phase 1 study found that pregabalin at doses up to 10 mg/kg/day in children aged one month to 16 years had acceptable safety and tolerability.¹³ Pediatric use remains more limited than adult use, though, and parents should expect that the prescribing conversation will be different for children.

Generalized Anxiety Disorder

This is where the prescribing picture depends on geography. In Europe, pregabalin is approved for generalized anxiety disorder (GAD). In the United States, it is not. American doctors sometimes prescribe it off-label for anxiety, but insurance coverage can be inconsistent because it lacks the FDA indication.

The evidence supporting its use for anxiety is actually quite strong. Randomized trials and meta-analyses show that pregabalin works for both the immediate treatment and relapse prevention of GAD, with some evidence of a faster onset than many traditional options.¹⁴ A head-to-head trial compared pregabalin against alprazolam (a benzodiazepine) and placebo; all three tested doses of pregabalin outperformed placebo, with anxiety relief appearing as early as the first week, matching the speed of alprazolam.¹⁵ That speed matters because SSRIs and SNRIs, the usual first-line drugs for GAD, typically take several weeks to kick in.

The appeal for anxiety is clear: pregabalin is not a benzodiazepine, so it avoids the severe dependence profile of drugs like alprazolam or clonazepam. It does carry its own dependence risks, though, which are covered below.

Where Lyrica Does Not Work Well

One of the most common off-label uses of pregabalin is for sciatica and lower back pain with a radiating nerve component. The evidence here is discouraging. A systematic review and meta-analysis found no statistically significant differences between pregabalin and placebo for leg pain, back pain, or disability at any time point measured, from two weeks out to a full year.¹⁶ A separate trial focused on chronic lumbosacral radiculopathy similarly failed to show a significant benefit over placebo.¹⁷

This is worth knowing because sciatica is extremely common, and some patients are prescribed pregabalin for it based on the logic that it works for other nerve pain conditions. The data suggest that sciatica pain involves a different enough mechanism that pregabalin’s calcium-channel approach does not offer much help. If you have been taking Lyrica for sciatica without noticeable improvement, the research supports having a conversation with your doctor about alternatives.

Common Side Effects

The most frequently reported side effects of pregabalin are dizziness, drowsiness, dry mouth, swelling in the hands and feet (peripheral edema), blurred vision, and weight gain. Most of these are dose-dependent, meaning they are more likely at higher doses and may diminish if the dose is reduced.

Weight gain deserves special mention because it is one of the main reasons people stop taking the drug. It tends to appear gradually over weeks to months and is thought to be related to increased appetite rather than fluid retention, though edema contributes for some patients.

Cognitive effects, commonly described as “brain fog” or difficulty concentrating, bother some people more than the pain relief helps. Drowsiness can be significant, especially when starting the medication or increasing the dose. One review of pregabalin’s use for restless legs syndrome described daytime sleepiness, headache, and unsteadiness as the main adverse effects, all categorized as mild.¹⁸ “Mild” in a clinical-trial context means they did not lead to many people dropping out, but in daily life, persistent drowsiness can feel quite disruptive.

The Opioid Interaction Problem

The most serious safety concern with pregabalin involves combining it with opioids. Both drug classes can suppress breathing, and the FDA has issued warnings about the increased risk of respiratory depression when gabapentinoids (pregabalin and gabapentin) are used alongside opioid painkillers, sedatives, or in patients with underlying lung disease.

Caution should be exercised when using pregabalin in combination with opioids for pain management.¹⁹ One study looking at postoperative patients found that the rate of respiratory depression episodes was similar whether or not patients also took a gabapentinoid, which muddies the picture somewhat.²⁰ But the real-world concern persists because many patients on pregabalin also take opioids, and the combination is now flagged by multiple regulatory agencies worldwide. If you are prescribed both, your doctor should be monitoring for signs like excessive sedation, shallow breathing, or unusual confusion.

Dependence and Withdrawal

Pregabalin is a Schedule V controlled substance in the United States, the lowest level of scheduling. That classification acknowledges a real, if modest, potential for misuse. At prescribed doses, physical dependence can still develop, and stopping abruptly can trigger withdrawal symptoms including insomnia, nausea, headache, anxiety, and sweating.

Case reports have documented withdrawal symptoms even in patients taking regular prescribed doses who had no history of substance abuse or psychiatric disorders.²¹ This is an underappreciated point. Most of the early attention on pregabalin withdrawal focused on people taking high doses recreationally, but it can happen to anyone who has been on the medication long enough for their nervous system to adapt. Tapering gradually under medical supervision, rather than stopping cold turkey, is the standard recommendation.

Pregnancy Considerations

The safety of pregabalin during pregnancy has been studied increasingly over the past decade, and the picture is more reassuring than initially feared, though not entirely settled. A large meta-analysis pooling data from over three million pregnancies found no statistically significant increase in major birth defects with first-trimester pregabalin monotherapy.²² An earlier study using two large databases found that after adjusting for other factors, the pooled risk of malformations was not significantly elevated for pregabalin monotherapy.²³

A Nordic population study raised a possible signal for stillbirth risk, but the finding weakened substantially after further statistical adjustment and the authors urged cautious interpretation.²⁴ The overall takeaway is that a small risk cannot be completely ruled out, but the data do not support the idea that pregabalin is strongly teratogenic. Women who become pregnant while on pregabalin should talk to their prescriber rather than stopping the drug abruptly, since withdrawal itself carries risks.

How Pregabalin Compares to Gabapentin

Pregabalin and gabapentin are close relatives, both classified as gabapentinoids, and they are frequently compared. A 2024 systematic review and meta-analysis of 14 studies with over 3,300 patients found that pregabalin showed better pain reduction on visual analog scales across time periods up to 12 to 14 weeks compared to gabapentin. Patients on pregabalin also reported better quality-of-life scores, more days with no or mild pain, and fewer days with severe pain. Opioid use was lower in the pregabalin group as well.²⁵

Gabapentin had a higher rate of nausea and vomiting in those studies, which is a somewhat unexpected pattern since both drugs share the same mechanism. The pharmacokinetic differences likely explain the clinical gap: gabapentin has erratic absorption that does not scale linearly with dose, meaning that as you take more, a smaller proportion actually reaches your bloodstream. Pregabalin’s absorption is far more predictable and nearly complete at any dose.² In practice, this means doctors can titrate pregabalin more confidently, and patients are more likely to get a consistent response.

Gabapentin does have one practical advantage: cost. It has been generic for much longer and is often significantly cheaper. Since pregabalin went generic in the U.S. in 2019, the price gap has narrowed, but gabapentin remains the less expensive choice in many cases. Doctors sometimes start with gabapentin and switch to pregabalin if the response is inadequate or side effects are problematic.

Risks in Older Adults

Pregabalin’s side effects are not equally distributed across age groups. Older adults are more vulnerable to dizziness, drowsiness, and unsteadiness, all of which increase fall risk. A retrospective study of critically ill patients aged 60 and older found that pregabalin use was associated with roughly 1.9 times the odds of developing delirium compared to non-use, and that association held up across multiple statistical adjustments.²⁶

This does not mean pregabalin cannot be used in older patients, but it does mean the starting dose should be lower, titration should be slower, and kidney function should be checked, since age-related declines in kidney clearance will cause the drug to accumulate. Falls and delirium are among the most consequential health events for older adults, so the risk-benefit calculation shifts compared to a 35-year-old with the same condition.

What Improvement Actually Looks Like

Clinical trials measure pain on numeric scales, but patients care about whether they can sleep through the night, go to work, and feel like themselves. Studies tracking patient-reported outcomes show that pregabalin consistently improves sleep quality and reduces how much pain interferes with daily life, particularly at doses of 300 mg per day or higher.²⁷ In primary care settings, patients on pregabalin reported improvements across a broad set of outcomes including pain severity, sleep, mood, and disability.²⁸

One comparative study found that about three-quarters of patients on pregabalin rated themselves as at least minimally improved after eight weeks, a figure nearly identical to patients receiving a different treatment approach (high-concentration capsaicin patches).²⁹ The effects on mental health and overall quality of life are less consistent than the effects on sleep and pain, though, which suggests that pregabalin addresses certain dimensions of chronic pain conditions more reliably than others.